Clinical trials: Neuron Disease, Motor
Spinal Muscular Atrophy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers
The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body.
- Trial name
- NCT02633709
- Testing
- Itraconazole, Risdiplam
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis
Virtual Task in Amyotrophic Lateral Sclerosis
Thirty individuals with ALS (18 men and 12 women, mean age 59 years, range 44-74 years), and 30 healthy controls matched for age and gender, participated.
- Trial name
- NCT03113630
- Testing
- Acquisition on TouchScreen, Acquisition on Kinect, Acquisition on LeapMotion
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Registry
This study takes amyotrophic lateral sclerosis (ALS) patients as the main research object. Through collecting genetics, imaging and clinical symptoms for Exploratory research, we will construct the gene spectrum of ALS in China…
- Trial name
- NCT05892822
- Testing
- Amyotrophic Lateral Sclerosis
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- yilong Wang
Amyotrophic Lateral Sclerosis
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.
- Trial name
- ALSummit (NCT04745299)
- Testing
- Lenzumestrocel, Riluzole
- Where
- 5 sites in South Korea
- Volunteers
- 123 people
- Sponsor
- Corestemchemon, Inc.
Muscular Atrophy, Spinal
Newborn Screening for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare, treatable, genetic disease that typically occurs in infancy and early childhood. SMA progressively, and irreversibly, destroys motor neurons in the brainstem and spinal cord, which control…
- Trial name
- SMA-NBS (NCT05481164)
- Where
- 9 sites in United Kingdom
- Volunteers
- 33,568 people
- Sponsor
- University of Oxford
Spinal Muscular Atrophy
Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy
The purpose of this trial is to evaluate the safety and tolerability of intrathecal administration of onasemnogene abeparvovec-xioi in infants and children with Spinal Muscular Atrophy with 3 copies of SMN2 and deletion of SMN1.
- Trial name
- STRONG (NCT03381729)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Gene Therapies
Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]
Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease of motor neurons. In the early 1980s, Werdnig from Vienna University and Hoffman from Heidelberg University described this disorder.
- Trial name
- NCT02855112
- Testing
- Adipose derived mesenchymal stem cell
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Tehran University of Medical Sciences
Amyotrophic Lateral Sclerosis
Repetitive Transcranial Magnetic Stimulation as Therapy for Depression in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms.
- Trial name
- NCT03892863
- Testing
- active repetitive transcranial magnetic stimulation
- Where
- Poland
- Sponsor
- Jagiellonian University
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide…
- Trial name
- NCT06556394
- Testing
- RAG-17
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- Ractigen Therapeutics.
Amyotrophic Lateral Sclerosis
Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis
The measurement of the facial deformation according to the body posture will be conducted by 3D scanning for each posture after marking the landmarks on the face.
- Trial name
- NCT04798183
- Testing
- 3-dimensional scan
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pusan National University Yangsan Hospital
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Digital Assessment of Speech and Fine Motor Control in ALS
This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
- Trial name
- NCT06315673
- Testing
- Digital Speech and Handwriting Assessment
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Spinal Muscular Atrophy, Developmental Delay
Effects of Developmental Support for Mothers of Infants With Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder causing progressive muscle weakness and atrophy.
- Trial name
- NCT07547189
- Testing
- Online Early Intervention Program for Infants with SMA Type 1
- Where
- Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Medipol University
Amyotrophic Lateral Sclerosis
The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS.
- Trial name
- RNS60 (NCT03456882)
- Testing
- RNS60
- Where
- 23 sites in United States, Italy
- Volunteers
- 147 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen A Zilucoplan
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT04436497
- Testing
- Zilucoplan
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy
Study of ALS Reversals 2: Genetic Analyses
The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place.
- Trial name
- StAR2 (NCT03464903)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
- Trial name
- ADORE (NCT05178810)
- Testing
- FAB122
- Where
- 38 sites in Belgium, France and 9 more
- Volunteers
- 313 people
- Sponsor
- Ferrer Internacional S.A.
Amyotrophic Lateral Sclerosis
Developing a Discrimination Model to Diagnose ALS
To combine several brain imaging techniques to develop a new diagnostic test to help with earlier diagnosis of amyotrophic lateral sclerosis.
- Trial name
- NCT01995903
- Testing
- MRI(magnetic resonance imaging)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis, Caregiver Burden
A Mindful Community for People With ALS and Their Primary Caregivers
The psychological impact of ALS on patients and caregivers is high, significantly affecting their quality of life (QOL). Despite this impact, there is not much research about psychological interventions that could reduce…
- Trial name
- NCT05595850
- Testing
- Mindfulness, Mindful Learning
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Harvard University
Amyotrophic Lateral Sclerosis
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
This is a 48-week, randomised, multi-centre, double-blind, placebo-controlled, parallel group investigation of the efficacy and safety of intravenous (IV) ozanezumab (GSK1223249) compared to placebo in subjects with Amyotrophic…
- Trial name
- NCT01753076
- Testing
- Ozanezumab
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis (ALS)
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00214110
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Wisconsin, Madison